Kornimate/medical-research-clean huggingface dataset:
ai and vr devices for eating behavior rehabilitation

Conditions: Eating Disorders; Anorexia Nervosa; Bulimia Nervosa

Summary: eating disorders (ed) affect the relationship with food and body image. virtual reality (vr), combined with artificial intelligence (ai), offers new clinical solutions, overcoming traditional cognitive behavioral therapy (cbt). the arcadia vr project aims to develop devices to treat ed through personalized vr systems (e.g. enhanced body-swap for anorexia, emotional rescripting for bulimia) and ai predictive algorithms to monitor severity, risk and efficacy of treatments. these approaches promise better and faster results, improving diagnosis and treatment.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of anorexia nervosa or bulimia nervosa according to dsm-5-tr (apa, 2013) and icd-11, confirmed by a public hospital setting * body mass index (bmi) between 16 and 32 * disorder present for at least 6 months * no other concurrent psychotherapeutic interventions during the study * all participants with a previous diagnosis will be re-evaluated and confirmed through assessment and consent by expert professionals in the research team (i.e., a neuropsychiatrist and a clinical psychologist)

Keywords: eating disorders anorexia nervosa bulimia nervosa virtual reality artificial intelligence body perception emotional regulation cognitive behavioral therapy
impact of radiofrequency ablation on left ventricular function in supraventricular tachyarrhythmias patient using speckle tracking echocardiography

Conditions: Left Ventricular Function, Arrhythmia

Summary: in this study, we aimed to evaluate atrial and ventricular function in supraventricular tachyarrhythmia patients before and 3 months after rfa using 2dste.

two-dimensional speckle-tracking echocardiography (2dste) is a known technique for the evaluation of myocardial function in many conditions. the longitudinal deformation of the left ventricular (lv) mainly occurs in the subendocardial level which is sensitive to injury and it may be used to identify sub-clinical lv dysfunction in cardiomyopathies. global longitudinal strain, strain rate (sr), and torsion measurements are very promising to identify patients with mild systolic and diastolic dysfunctions which are not reflected in reduced ef. tachyarrhythmias that are persistent and recurrent can lead to lv dysfunction. dyssynchrony is another mechanism that may cause lv dysfunction, as in the case of wolf parkinson syndrome (wpw ). it might be explained by the "collision" of electric stimuli through the normal atrioventricular conduction system and along the accessory pathway (ap) during the systolic phase. 2dste has been used to investigate the characteristics of wpw syndrome and confirm the presence of lv dyssynchrony in this condition. lelakowski et al. showed that rfa improves lv systolic and diastolic functions in patients with atrioventricular nodal reentry tachycardia (avnrt). recurrent avnrt attacks increase atrial pressure, leading to elevated atrial wall stress, which causes negative remodeling and systolic impairment. it has been shown that left atrial(la) functions improved after radiofrequency ablation rfa, along with la volume reduction in atrial fibrillation/flutter patients. the small number of patients and lacking using advanced accurate techniques lead to currently insufficient data in the literature regarding changes in cardiac function following avnrt \& avrt ablation and whether lv dyssynchrony is reversible after ablation therapy of avrt or not.

Eligibility criteria:
inclusion criteria: - patients with avnrt or avrt undergoing rf ablation exclusion criteria: * - patient with bundle blocks * coronary artery disease * diastolic dysfunction ≥grade 2 * left ventricular hypertrophy * diabetes mellitus * chronic renal failure (gfr\<45ml\\min) * moderate to severe valvular heart disease * patient with bad echo window
the effect of acupuncture on pregnancy rates in women undergoing embryo transfer

Conditions: Pregnancy

Summary: the present study is designed to test the hypothesis that acupuncture, before and after embryo transfer, significantly improves pregnancy rates, compared to embryo transfer with sham acupuncture and no acupuncture at all.


Eligibility criteria:
inclusion criteria: * patient is undergoing embryo transfer after ivf or icsi * patient has given informed consent to participate exclusion criteria: * frozen embryo transfer * previous enrollment in study

Keywords: infertility ivf acupuncture
decitabine followed by a cancer antigen vaccine for patients with neuroblastoma and sarcoma

Conditions: Neuroblastoma; Ewings Sarcoma; Osteogenic Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma

Summary: this treatment study for relapsed high-risk neuroblastoma, ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma involves an autologous cancer testis (ct) antigen specific dendritic cell (dc) vaccine preceded by decitabine as a demethylating chemotherapy.

for vaccine production, mature dc will be pulsed with overlapping peptides mixes derived from full-length ny-eso-1, mage-a1, and mage-a3.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of relapsed high-risk neuroblastoma,ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma, synovial sarcoma * patient may have gross tumor that has been treated with multi-agent chemotherapy prior study entry, but does not need to have gross tumor prior to study entry. * patients must have had a diagnosis of neuroblastoma or sarcoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines. * have received standard chemotherapy and/or sct, and are at least 6 months post-transplant. * age: patients must be 1 - \< 25 years of age when registered on study. * organ function requirements: all patients must have adequate organ function defined as: * hematological function: anc ≥ 500; platelet count ≥ 75. * renal function: creatinine clearance or radioisotope gfr ≥ 70ml/min/1.73 m2 or a maximum serum creatinine (mg/dl) based on age/gender as follows: 1yo m\&f = 0.6, 2-5yo m\&f = 0.8, 6-9yo m\&f = 1, 10-12yo m\&f = 1.2, 13-15yo m = 1.5, 13-15yo f = 1.4, 16+ m = 1.7, 16+ f = 1.4 * cardiac function: patient must have normal cardiac function documented by ejection fraction (\> 55%) documented by echocardiogram or radionuclide muga evaluation or fractional shortening (≥ 28%) documented by echocardiogram * liver function: total bilirubin ≤ 1.5 x normal for age, and sgpt (alt) and sgot (ast) ≤ 3 x normal for age. * room air pulse oximetry \>94%. * male and female sexually active patients of reproductive age who wish to participate must agree to use acceptable contraception. * lansky performance scale \> 70, ecog \< 2 (appendix i). exclusion criteria: * patient is pregnant. * patients with a positive result for any of the following diagnostic tests: hep b ag, hep b core ab, hep c ab, hiv-1 ab, hiv-2 ab, htlv-1 ab, htlv-2 ab, rpr. * patient has a history of autoimmune disease, specifically inflammatory bowel disease, systemic lupus erythematosis, or rheumatoid arthritis. * patient is receiving concurrent systemic steroid therapy. * patient has a known systemic hypersensitivity to dac, hiltonol, or any vaccine component.

Keywords: neuroblastoma ewings sarcoma osteogenic sarcoma rhabdomyosarcoma synovial sarcoma high-risk relapsed children
beat-to-beat variability in persistent atrial fibrillation

Conditions: Persistent Atrial Fibrillation

Summary: heart rate variability (hrv) in patients with atrial fibrillation (af) is hardly studied. though a reduced hrv in patients with heart failure and reduced ejection fraction (hfref) has been associated with poor prognosis. data on hrv in af-patients without a reduced ejection fraction is lacking. we hypothesize that those patients with persistent atrial fibrillation and larger beat-to-beat variability would be more symptomatic than does those with smaller hrv. to asses this theory we intend to perform a prospective observational trial. symptoms of atrial fibrillation will be assessed using quality of life questionnaires and 6 minutes walking test. heart rate variability will be assessed using 24 hour holter ecg monitoring. the correlation between symptoms and heart rate variability will be then assessed.


Eligibility criteria:
inclusion criteria: * persistent atrial fibrillation * no previous ablation for atrial fibrillation * at least 18 years old * signed written patient's informed consent exclusion criteria: * paroxysmal atrial fibrillation * previous ablation therapy for atrial fibrillation * reduced left ventricular ejection fraction (lvef\<35%) * permanent ventricular pacing (including cardiac resynchronization therapy crt) * acute coronary syndrome (acs) during past 6 weeks. * stroke or tia within past 6 weeks. * cardiac surgical operation/ intervention within past 3 months. * acute decompensated heart failure * treatment with iv inotropic medications (e.g. dobutamine, levosimendan) * mitral valve replacement or rheumatic mitral valve stenosis * neurological or psychological disease that may impair patient's judgement or compliance * pregnancy or breast-feeding women.

Keywords: persistent atrial fibrillation heart rate variability quality of life
efficiency study of siwu tang to treat brain hypoperfusion syndrome

Conditions: Brain Hypoperfusion Syndrome; Ischemia Brain

Summary: brain hypoperfusion patients may cause vascular dementia results from their hypoperfusion state except that is a risk factor for stroke. the most common clinical symptom of hypoperfusion syndrome is dizziness.siwu tang is made of angelica sinensis (oliv.) diels (當歸), rehmannia glutinosa (gaertn) libosch (熟地黃), paeonia lactiflora pall (白芍), ligusticum chuanxiong hort (川芎), and that was used to treat patients with blood deficiency for several centuries. the purpose of the present study was to investigate the complementary effect of siwu tang on brain hypoperfusion syndrome patients

we designed a randomized, double-blinded controlled study, and a total of 80 patients with brain hypoperfusion syndrome should be finished assessment in two years. the 80 patients with hypoperfusion syndrome were divided into as follows:1) control group, receiving siwu tang placebo 3 g bid continuously two weeks except ordinary treatment; 2) treatment group, receiving siwu tang 3 g bid continuously two weeks except ordinary treatment. the patients were assessed before, and 4 weeks (weeks±3 days) and 12 weeks (12 weeks±3 days) after siwu tang treatment, respectively. primary outcome measure was cerebral blood flow by using single photon emission computed tomography (spect); second outcome measure included severity of dizziness by using visual analogue scale (vas); cognitive function by using mini-mental status (mmse), cognitive abilities screening instrument (casi), and clinical dementia rating (cdr); quality of life by using barthel index (bi) and functional independent measure (fim). we predict that siwu tang can improve cerebral blood flow, and clinical manifestation including dizziness, and cognition function and quality of life in patients with brain hypoperfusion syndrome .

Eligibility criteria:
inclusion criteria: * age between 18y/o to 80 y/o and had brain hypoperfusion syndrome such as dizziness * barthel index (bi) \> 60。 * single photon emission computer tomography(spect) or mri exam show hypoperfusion area exclusion criteria: * patient had cancer or uremia,liver cirrhosis

Keywords: siwu tang brain hypoperfusion cognition function
a research study to understand how oral semaglutide works in people with type 2 diabetes in india

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to look at the change in blood sugar levels in participants with type 2 diabetes who start using oral semaglutide. participants will get oral semaglutide as prescribed to them by the study doctor. the study will last for about 8-11 months (34-44 weeks). participants will be asked to complete a questionnaire about how they take oral semaglutide tablets. participants will complete this questionnaire during the normal scheduled visit with the doctor and will be asked questions about their health and their diabetes treatment and lab tests as part of their normal doctor's appointment.


Eligibility criteria:
inclusion criteria: * signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * diagnosed with type 2 diabetes (t2d). * the decision to initiate treatment with commercially available oral semaglutide has been made by the patient/legally acceptable representative (lar) and the treating physician based on local label before and independently from the decision to include the patient in this study. * male or female, age above or equal to 18 years at the time of signing informed consent. * available glycated haemoglobin a1c (hba1c) value less than or equal to (\<=) 90 days prior to the 'informed consent and treatment initiation visit' (v1) or hba1c measurement taken in relation with the 'informed consent and treatment initiation visit' (v1) if in line with local clinical practice. * treatment naive to injectable glucose-lowering drug(s). an exception is short-term insulin treatment for acute illness for a total of less than or equal to (\<=) 14 days. exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study. * any prior or current use of oral semaglutide. * hypersensitivity to oral semaglutide or to any of the excipients. * treatment with any investigational drug within 30 days prior to signing of informed consent. * participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days prior to signing of informed consent. * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
tekitrust tests to determine the level of sars-cov-2/covid-19 neutralizing antibodies in the blood

Conditions: SARS-CoV2 Infection

Summary: the purpose of this study is to determine if the tekitrust enzyme-linked immunosorbent assay (elisa) kit and tekitrust rapid test can accurately determine the amount of antibodies to fight the covid-19 virus in sampled blood compared to the standard plaque reduction neutralization test (prnt) test. when a person has covid-19 they develop antibodies to the virus which are contained in their blood stream. after a certain period, the number of antibodies to fight (neutralize) the virus begin to decrease. one common way to measure the amount of antibodies in the blood is to use a test called the prnt. the focus of this study is to compare the ability of the tekitrust elisa kit and the tekitrust rapid test with the prnt to determine if these tests can measure the antibodies equally well.

participants who have been previously diagnosed with covid-19 within the past 3 months through any fda emergency use approved (eua) assay test will eligible for inclusion in the study. a blood and fingerstick sample will be obtained from the participant and for subjects with a positive test and symptom onset of less than 30 days a repeat rt-pcr nasal pharyngeal swab sample will be taken. the fingerstick sample will be used onsite by qualified site staff to test the tekitrust sars-cov-2 neutralizing antibody detection rapid test. these results will be compared to the whole blood sample sent to the lab which will be analysed for sars cov-2 neutralizing antibodies using the tekitrust sars-cov-2 neutralizing antibody detection elisa kit and the comparator plaque reduction neutralization test (prnt) test.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age 2. able and willing to provide written informed consent 3. previously diagnosed as sars-cov-2 positive by any fda eua approved assay with a symptom onset date within the previous 30 days and who are willing to provide a nasopharyngeal swab for rt-pcr testing 4. suspected of previous sars-cov-2 infection and willing to provide a nasopharyngeal swab for rt-pcr testing 5. previously diagnosed as sars-cov-2 positive by a fda eua approved rt-pcr assay with a symptom onset date greater than 30 days and a known date of pcr sample collection and symptom severity exclusion criteria: 1. any significant medical, psychological, or social condition which in the opinion of the investigator may preclude the subject from participating in the trial

Keywords: antibodies, neutralizing covid-19
interdisciplinary perioperative care in minimally-invasive heart valve surgery

Conditions: Heart Valve Diseases

Summary: valvular heart diseases are among the most common cardiac pathologies in adult patients in germany. currently, the process of care before, during and after heart valve surgery does not follow a standardized and interdisciplinary optimal approach. an approach already established in other surgical disciplines is the enhanced recovery after surgery (eras) protocol, which aims at optimizing the recovery process of patients. within the increase study, a care process inspired by the eras protocol will be established at the university heart and vascular center (uhz) of the university medical center hamburg-eppendorf (uke) and the university medical center augsburg (uka). executing the study at two facilities in different regions in germany will help to demonstrate transferability of the process of care. the effectiveness of this process compared to the current treatment approach will be investigated in a randomized controlled trial. a total of 186 patients will be allocated by chance either to the intervention group (eras protocol) or the control group (treatment as usual). patients in the intervention group will receive an optimized interdisciplinary care protocol including medical, nursing, physiotherapeutical and psychotherapeutical interventions. measurements of effectiveness are the number of hospitalized days (due to cardiac causes) within one year and the physical condition of the patient as measured by the 6-minute walk test (6mwt) on the day of discharge.


Eligibility criteria:
inclusion criteria: * indication for elective minimally invasive (open) aortic or mitral valve surgery * patient's ability to understand the nature and extent of the individual's requirements for participation in the new care setting * classification of the patient as "fit" or "pre-frail" using the lucas functional index (frailty index) (dapp et al. 2012) exclusion criteria: * limited life expectancy less than one year (e.g., advanced tumor disease) * urgent or emergency interventions * severe chronic obstructive pulmonary disease (gold iii or iv) * dialysis-dependant renal failure * advanced liver cirrhosis (child stages b + c) * severe comorbidities or psychosocial reasons that militate against participation or do not allow for written informed consent (e. g., residual neurological impairment after prior stroke, major restrictions of mobility, neuropsychological disorders, depressive disorder, substance-related addictive disorders) * lack of a social environment that can provide supportive patient care * previous cardiac surgery (i.e., relative contraindication for minimally invasive technique)

Keywords: randomized controlled trial enhanced recovery after surgery minimally invasive surgery postanesthesia care unit physiotherapy
immunogenicity and safety of vaccine against tetanus and diphtheria.

Conditions: Diphtheria; Tetanus

Summary: a single blind, randomized, comparative, multicentre clinical trial of the immunogenicity and safety of booster immunization with bivalent vaccine against tetanus and diphtheria clodivac (ibss biomed s.a.) and td-impfstoff mérieux (sanofi pasteur) in healthy adults.


Eligibility criteria:
inclusion criteria: 1. approved informed consent. 2. men and women aged 18- 65 years. 3. written confirmation on previous immunization against diphtheria and tetanus not older than 16 years and not younger than 4 years. exclusion criteria: 1. subject with acute infectious diseases. 2. subject allergic to any of the substances of the imp administered in clinical trial. 3. subject with guillain-barré syndrome or neuropathy, an anaphylactic or other allergic reactions after previous vaccination against tetanus or diphtheria. 4. subject with primary or secondary immunodeficiency (e.g. congenital immunodeficiency, hiv infection, organ or bone marrow transplantation, leukemia, lymphoma, hodgkin's disease, multiple myeloma, generalized malignancy, drugs or other causes induced immunodeficiency). 5. subject with progressive or unstable neurological disorder. 6. subject with severe thrombocytopenia or any coagulation disorder not allowing the intramuscular administration. 7. subject with blood product treatment, including immunoglobulins within the last 90 days prior to study entry. 8. subject vaccinated less than 14 days inactivated or live vaccine prior to study entry. 9. pregnant woman and breastfeeding (anamnestically). 10. subject incapable of cooperation. 11. alcohol or drug abuse. 12. subject currently participating in another clinical trial or in drug evaluation, within 4 weeks prior to study entry. 13. subjects requiring vaccination against tetanus after severe injury. 14. any other condition that in the investigator's opinion may affect the safety of the test participant or the integrity of data obtained during the study.

Keywords: vaccine booster